Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 8720342, 5 pages
http://dx.doi.org/10.1155/2016/8720342
Clinical Study

Myoinositol and D-Chiro Inositol in Improving Insulin Resistance in Obese Male Children: Preliminary Data

Pediatrics and Adolescent Andrological Project, Department of Pediatrics, San Paolo Hospital, Via di Rudini 8, University of Milan, 20142 Milan, Italy

Received 28 June 2016; Revised 20 September 2016; Accepted 5 October 2016

Academic Editor: Zdravko A. Kamenov

Copyright © 2016 Mario Mancini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. L. Croze and C. O. Soulage, “Potential role and therapeutic interests of myo-inositol in metabolic diseases,” Biochimie, vol. 95, no. 10, pp. 1811–1827, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Larner, “D-chiro-inositol—its functional role in insulin action and its deficit in insulin resistance,” International Journal of Experimental Diabetes Research, vol. 3, no. 1, pp. 47–60, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. A. D. Genazzani, C. Lanzoni, F. Ricchieri, and V. M. Jasonni, “Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 24, no. 3, pp. 139–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. L. C. Huang, M. C. Fonteles, D. B. Houston, C. Zhang, and J. Larner, “Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo,” Endocrinology, vol. 132, no. 2, pp. 652–657, 1993. View at Google Scholar · View at Scopus
  5. A. Bevilacqua, G. Carlomagno, S. Gerli et al., “Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology—assisted reproduction technology,” Gynecological Endocrinology, vol. 31, no. 6, pp. 441–446, 2015. View at Publisher · View at Google Scholar
  6. F. Facchinetti, M. Bizzarri, S. Benvenga et al., “Results from the international consensus conference on Myo-inositol and d-chiro-inositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS,” European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 195, pp. 72–76, 2015. View at Publisher · View at Google Scholar
  7. M. Minozzi, M. Nordio, and R. Pajalich, “The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 4, pp. 537–540, 2013. View at Google Scholar · View at Scopus
  8. J. Larner, D. L. Brautigan, and M. O. Thorner, “D-chiro-inositol glycans in insulin signaling and insulin resistance,” Molecular Medicine, vol. 16, no. 11-12, pp. 543–551, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Cacciari, S. Milani, A. Balsamo et al., “Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr),” Journal of Endocrinological Investigation, vol. 29, no. 7, pp. 581–593, 2006. View at Publisher · View at Google Scholar
  10. INRAN (Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione), Italian Guidelines for a healthy diet, 2003, http://nut.entecra.it/files/download/linee_guida/lineeguida_intro.pdf
  11. Società Italiana di Pediatria (SIP) (Italia Society of Pediatrics), Chilhood Obesity: Consensus on Prevention, Diagnosis and Therapy, http://www.ecog-obesity.eu/papers/Consensus_Italia.pdf
  12. Società Italiana di Nutrizione Umana (SINU) and Italian Society oh Human Nutrition, Nutrients and Energy Reference Intake Levels, Società Italiana di Nutrizione Umana, Milano, Italy, 2014.
  13. World Health Organization (WHO), “Recommended population levels of physical activity for health,” in Global Recommendations on Physical Activity for Health, World Health Organization, Geneva, Switzerland, 2010. View at Google Scholar
  14. M. M. Mukaka, “Statistics corner: a guide to appropriate use of correlation coefficient in medical research,” Malawi Medical Journal, vol. 24, no. 3, pp. 69–71, 2012. View at Google Scholar · View at Scopus
  15. J. Larner, “D-chiro-inositol in insulin action and insulin resistance—old-fashioned biochemistry still at work,” IUBMB Life, vol. 51, no. 3, pp. 139–148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Whiting, R. N. Danaher, K. Ruggiero et al., “D-chiro-inositol attenuates epinephrine-stimulated hepatic glucose output in the isolated perfused liver independently of insulin,” Hormone and Metabolic Research, vol. 45, no. 5, pp. 394–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Larner, G. Allan, C. Kessler, P. Reamer, R. Gunn, and L. C. Huang, “Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 9, no. 2–4, pp. 127–137, 1998. View at Google Scholar · View at Scopus
  18. H. K. Ortmeyer, L. C. Huang, L. Zhang, B. C. Hansen, and J. Larner, “Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys,” Endocrinology, vol. 132, no. 2, pp. 646–651, 1993. View at Google Scholar · View at Scopus
  19. S. H. Bates, R. B. Jones, and C. J. Bailey, “Insulin-like effect of pinitol,” British Journal of Pharmacology, vol. 130, no. 8, pp. 1944–1948, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. H. K. Ortmeyer, N. L. Bodkin, B. C. Hansen, and J. Larner, “In vivo D-chiroinositol activates skeletal muscle glycogen synthase and inactivates glycogen phosphorylase in rhesus monkeys,” The Journal of Nutritional Biochemistry, vol. 6, no. 9, pp. 499–503, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. J.-I. Kim, J. C. Kim, M.-J. Kang, M.-S. Lee, J.-J. Kim, and I.-J. Cha, “Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study,” European Journal of Clinical Nutrition, vol. 59, no. 3, pp. 456–458, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Davis, M. Christiansen, J. F. Horowitz, S. Klein, M. K. Hellerstein, and R. E. Ostlund Jr., “Effect of pinitol treatment on insulin action in subjects with insulin resistance,” Diabetes Care, vol. 23, no. 7, pp. 1000–1005, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Unfer, G. Carlomagno, G. Dante, and F. Facchinetti, “Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials,” Gynecological Endocrinology, vol. 28, no. 7, pp. 509–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. D. Genazzani, S. Santagni, E. Rattighieri et al., “Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients,” Gynecological Endocrinology, vol. 30, no. 6, pp. 438–443, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Celentano, B. Matarrelli, P. A. Mattei, G. Pavone, E. Vitacolonna, and M. Liberati, “Myo-inositol supplementation to prevent gestational diabetes mellitus,” Current Diabetes Reports, vol. 16, article 30, 2016. View at Publisher · View at Google Scholar
  26. R. D'Anna and A. Scilipoti, “Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes,” Diabetes Care, vol. 36, no. 4, pp. 854–857, 2013. View at Publisher · View at Google Scholar